Anebulo Pharmaceuticals (ANEB)
(Delayed Data from NSDQ)
$2.33 USD
-0.07 (-2.92%)
Updated Jul 25, 2024 09:30 AM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ANEB 2.33 -0.07(-2.92%)
Will ANEB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANEB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANEB
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
ANEB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
Other News for ANEB
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Anebulo gets $1.9M cooperative grant award from NIDA for intravenous selonabant
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
Anebulo Pharmaceuticals GAAP EPS of -$0.06 beats by $0.06